04:58:58 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-03-13 Årsstämma 2024
2024-01-30 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-25 Kvartalsrapport 2023-Q2
2023-04-25 Kvartalsrapport 2023-Q1
2023-03-13 Ordinarie utdelning OSSR 0.00 DKK
2023-03-10 Årsstämma 2023
2023-01-31 Bokslutskommuniké 2022
2022-10-25 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-03-09 Ordinarie utdelning OSSR 0.00 DKK
2022-03-08 Årsstämma 2022
2022-02-01 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-09 Ordinarie utdelning OSSR 0.00 DKK
2021-03-08 Årsstämma 2021
2021-02-02 Bokslutskommuniké 2020
2020-10-27 Kvartalsrapport 2020-Q3
2020-07-23 Kvartalsrapport 2020-Q2
2020-04-30 Kvartalsrapport 2020-Q1
2020-03-13 Ordinarie utdelning OSSR 0.15 DKK
2020-03-12 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-30 Kvartalsrapport 2019-Q1
2019-03-08 Ordinarie utdelning OSSR 0.14 DKK
2019-03-07 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-25 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-09 Ordinarie utdelning OSSR 0.13 DKK
2018-03-08 Årsstämma 2018
2018-02-05 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-07-25 Kvartalsrapport 2017-Q2
2017-04-27 Kvartalsrapport 2017-Q1
2017-03-10 Ordinarie utdelning OSSR 0.12 DKK
2016-03-11 Ordinarie utdelning OSSR 0.12 DKK
2016-03-10 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-07-23 Kvartalsrapport 2015-Q2
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-12 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Analytiker möte 2014


ListaLarge Cap Copenhagen
Össur hf. är ett isländskt bolag verksamma inom hälsa - och sjukvård. Idag innehas affärsinriktning mot utvecklandet av benproteser, artros samt relaterad skadehantering. Produkterna är anpassade för olika åldrar och förutsättningar beroende på patientens svårighetsgrad. Verksamheten är etablerad globalt med störst marknad inom Europa följt av Nordamerika. Huvudkontoret ligger i Reykjavik.
2023-04-25 08:00:00

Announcement no. 13/2023

Interim report Q1 2023

25 April 2023

Sveinn Sölvason, President and CEO, Comments:

"Sales amounted to 181 million and the EBITDA margin before special items was 16% in Q1 2023. The organic growth was strong at 9% driven by growth in all regions and all business segments. Despite inflation driven OPEX growth and FX headwinds, we see a healthy development in operating profit. At the end of March, we held our Capital Markets Day in Copenhagen where we introduced our Growth'27 strategy and our new sales segmentation which includes the three business segments; Prosthetics, Bracing & Supports and Patient Care. We presented our growth ambition of 7-10% average local currency growth over the Growth'27 period, in FY 2023-2027. We are focused on reaching more people that need mobility solutions and will drive accelerated organic growth focusing on Patient Reach, Innovative Solutions and O&P Value Creation."

Highlights Q1 2023
  • Sales amounted to USD 181 million in Q1 2023. Sales growth was 11% in local currency and increased by 9% organic, compared to 10% in local currency and 6% organic in Q1 2022.
  • Prosthetics sales grew by 13% organic, Bracing & Supports (B&S) sales increased by 5% organic and Patient Care sales grew by 8% in Q1 2023, compared to 10%, 6% and 2% respectively, in Q1 2022.
  • FX changes resulted in USD 8 million lower reported sales in Q1 2023, when comparing to Q1 2022.
  • Gross profit margin was 62% in Q1 2023, the same as in Q1 2022.
  • EBITDA before special items amounted to USD 28 million in Q1 2023, and the EBITDA margin before special items was 16%, also the same as in Q1 2022.
  • Net profit in Q1 2023 amounted to USD 10 million or 6% of sales compared to USD 9 million or 5% of sales in Q1 2022.
  • Cash generated by operations amounted to USD 13 million or 7% of sales in Q1 2023.
  • NIBD/EBITDA before special items was 3.2x (2.7x without lease liabilities) at the end of Q1 2023, above the target ratio of 2.0-3.0x. In line with Össur's Capital Structure and Capital Allocation Policy, Össur continues to temporarily pause share buybacks as NIBD/EBITDA before special items is temporarily above the target leverage range.
  • The financial guidance for the full year 2023 is 4-8% organic sales growth, 17-20% EBITDA margin before special items, 3-4% CAPEX of sales, and an effective tax rate of 23-24%.

Q1 2023 conference call details

Össur will host a conference call on 25 April 2023 at 9:00 CEST / 7:00 GMT / 3:00 ET. To participate in the call, please click on this link: Össur Conference Call (https://register.vevent.com/register/BIf5d63d8834a5435487634df1946fb109)

A webcast can be followed on the Össur website: http://www.ossur.com/investors

Further information

Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com,+354 844 4759

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors

About Össur

Össur (Nasdaq Copenhagen: OSSR) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®. For over 50 years, Össur has had a strong purpose rooted in positively impacting people's health and well-being. A recognized "Technology Pioneer", Össur focuses on improving people's mobility through the delivery of solutions that advance patient care. Significant investment in research and development has led to over 2,000 patents, award-winning designs, successful clinical outcomes, and steady growth. Össur is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women's Empowerment Principles, and contributes to the UN Sustainable Development Goals. Össur operates globally and has around 4,000 employees. www.ossur.com